Heart failure & cardiomyopathies
Hypophosphataemia Risk Associated with Ferric Carboxymaltose in Heart Failure: A Pooled Analysis of Clinical Trials
Authors' conclusion
The risk of laboratory-assessed hypophosphataemia in HF patients treated with FCM was lower than that seen in patients in other therapeutic areas treated with FCM, and clinical events associated with hypophosphataemia are uncommon with FCM therapy in this population.
Study context
- Population
- Adults with iron deficiency across disease states and therapeutic areas treated with intravenous ferric carboxymaltose (FCM)
- Participants
- 7,931 adults41 studies
- Comparison
- Hypophosphataemia incidence with FCM across therapeutic areas
- Outcome
- Post-baseline moderate or severe hypophosphataemia (serum PO4 3- <2.0 mg/dL)
Pooled result
As reported in the abstract
Further pooled results
| Outcome | HF | Neurology | Gastrointestinal | OR |
|---|---|---|---|---|
| Serum PO4 3- <1.0 mg/dL | <0.1% | 4.8% | 4.0% | |
| Predictor of hypophosphataemia: preserved kidney function (eGFR >60 vs <30 mL/min/1.73 m²)Strongest predictor | 12.2 |
Mean serum PO4 3- over time
- Except haemodialysis-dependent chronic kidney disease (HD-CKD), mean serum PO4 3- decreased through weeks 2 to 4, then returned toward baseline and plateaued by week 8
Safety
TEAEs potentially related to hypophosphataemia (heart failure (HF) subgroup)
- Lower with FCM than placebo
- Lower with post-baseline PO4 3- <2 mg/dL than without
Original publication
Hypophosphataemia Risk Associated with Ferric Carboxymaltose in Heart Failure: A Pooled Analysis of Clinical Trials. ESC Heart Fail. Published 1 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →